News

News

@AIHTA

Welcome to the homepage of AIHTA!

AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.

In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.

Subscribe to newsletter

©Juan Gärtner

Announcement

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce our four new HSO Fact Sheets.

Fact Sheet No. 11 (Mai 2020)
Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer

Fact Sheet No. 12 (Mai 2020)
Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer

Fact Sheet No. 13 (Mai 2020)
Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC

More...

©freshidea

Project / Psychological & psychiatric interventions

Effectiveness of music therapy

Project leaders: Claudia Wild

Project team: Lucia Gassner, Julia Mayer-Ferbas

Laufzeit: Juni bis Oktober 2020
Sprache: Englisch mit deutscher Zusammenfassung

More...

©Mike Fouque

Announcement

Covid-19: HSS/ Horizon Scanning Living Document (v03 June 2020)

he establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

All work steps are conducted in close international (European) cooperation.

Publication: Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild

More...

©Stefan Yang

Announcement

Proton and carbon ion therapy – an update on indications

Worldwide, 82 particle therapy facilities are currently in clinical operation; further 37 centers are under construction or in planning. This means that the number of centres worldwide has more than doubled since 2013. In Europe alone, 27 centres are currently operational (2013: 14). With such a large number of treatment centers, it should be assumed that the underlying clinical evidence on patient benefit is convincing. The update of the LBI-HTA report 2013 has the task to give an overview of secured indications as well as indications that are only recommended under clinical research. Only a hand search for HTA reviews and systematic reviews was conducted. The identified reviews articulate in unison that the available - mostly retrospective - studies are of low quality and insufficient to make conclusive statements on the added value of proton or carbon ion therapy. Only a few indications are recommended for proton or carbon ion therapy (chordomas and chondrosarcomas, uveamelanoma, pediatric tumors in the base of the skull, brain and head and neck tumors) to avoid secondary tumors. Further indications, with curative intention and non-metastatic, are only recommended under conditions of prospective clinical studies.

Publication: AIHTA Policy Brief Nr.: 004: http://eprints.aihta.at/1245/
Contact: Claudia Wild

More...

Note: this content is only available in German.

Inhalt

Zur Druckversion...

©Juan Gärtner

Announcement

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce our four new HSO Fact Sheets.

Fact Sheet No. 7 (April 2020)
Encorafenib (Braftovi^®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation

Fact Sheet No. 8 (April 2020)
Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen

Fact Sheet Nr. 9 (April 2020)
Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma

Fact Sheet No. 10 (April 2020)
Glasdegib (Daurismo^®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML)

More...

©elenabsl

Project / HTA-methods & steering instruments

Framework for reimbursement decisions of digital health technologies (mHealth) and its (retrospective) application on selected examples

Project leaders: Claudia Wild

Project team: Reinhard Jeindl, Claudia Wild

Duration: May 2020 – November 2020
Language: German (with English summary)

More...

©T.L.Furrer

Project / Health economics

ThemenCheck Medizin (IQWIG): Depression in children and adolescents - Does psychotherapy lead to better results compared to other therapies? (HT19-04) (Health Economics and Ethics)

Project leaders: Ingrid Zechmeister-Koss

Project team: Michal Stanak, Christoph Strohmaier

Duration: January 2020 – September 2020
Language: German
In co-operation with: Department for Evidence Based Medicine / DUK

More...

Note: this content is only available in German.

Inhalt

Zur Druckversion...

©Mike Fouque

Announcement

Covid-19: HSS/ Horizon Scanning Living Document (v02 May 2020)

The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

All work steps are conducted in close international (European) cooperation.

Publication: Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild

More...